Press Release Archive 1998-2005

2005

December 14, 2005: Cytokinetics Announces Seven Poster Presentations at the 45th Annual American Society of Cell Biology Meeting

December 13, 2005: Cytokinetics Announces Selection of Development Candidate Directed to Second Mitotic Kinesin Target

December 8, 2005: Cytokinetics Announces Presentation of Ispinesib data at San Antonio Breast Cancer Symposium

December 7, 2005: Cytokinetics Announces Selection of CK-1827452 as Development Candidate for Chronic Heart Failure

December 7, 2005: Cytokinetics Announces Seven Posters to be Presented at the 45th Annual American Society of Cell Biology Meeting

December 2, 2005: Cytokinetics Sponsors Fourth Special Interest Subgroup on Function and Regulation of Actin-Myosin Interactions

December 1, 2005: Cytokinetics Announces Interim Phase II Breast Cancer data for Ispinesib to be presented at San Antonio Breast Cancer Symposium

November 22, 2005: Cytokinetics to Present at the Lazard Capital Markets Life Sciences Conference

November 17, 2005: Cytokinetics Announces Clinical and Non-Clinical Results for Ispinesib at the 2005 Annual AACR-NCI-EORTC Meeting

November 11, 2005: Cytokinetics to Present at the Credit Suisse First Boston Health Care Conference

November 10, 2005: Cytokinetics Announces Clinical and Non-Clinical Data on Ispinesib to be Presented at the 2005 AACR-NCI-EORTC International Meeting

October 31, 2005: Cytokinetics to Present at the Rodman & Renshaw Techvest 7th Annual Healthcare Conference

October 28, 2005: Cytokinetics Secures $75 Million Committed Equity Financing Facility

October 26, 2005: Cytokinetics, Incorporated Reports Third quarter 2005 Financial Results

October 19, 2005: Cytokinetics to Announce Third Quarter Results on October 26, 2005

October 12, 2005: Cytokinetics to Present at BIO InvestorForum 2005

September 27, 2005: Cytokinetics Provides Clinical Trials Update for Ispinesib (SB-715992)

September 27, 2005: Cytokinetics and GlaxoSmithKline Amend Collaboration Agreement for SB-743921; Maturation of Cytokinetics’ Capabilities Enables Increased Responsibility for Clinical Development under Augmented Development Program for KSP Inhibitors

September 19, 2005: Cytokinetics Presents Data on CK-1827452 at the 2005 Annual Heart Failure Society of America Meeting; Non-Clinical Research Findings Support Advancement of Drug Candidate

September 12, 2005: Cytokinetics to Present Non-Clinical Data On CK-1827452 At the 2005 Annual Heart Failure Society of America Meeting

September 6, 2005: Cytokinetics to Present at the Bear Stearns 18th Annual Healthcare Conference

September 6, 2005: Cytokinetics Announces the Initiation of a Phase I Clinical Trial of CK-1827452 for the Treatment of Acute Heart Failure; Cardiac Myosin Activator Extends Validation of Cytoskeletal Platform

September 2, 2005: Cytokinetics to Present at the 12th Annual NewsMakers in the Biotech Industry Conference

July 27, 2005: Cytokinetics, Incorporated Reports Second Quarter 2005 Financial Results; Company Announces the Initiation of Two Additional Clinical Trials for Ispinesib and the Advancement of Its Lead Cardiac Myosin Activator, CK-1827452

July 27, 2005: Cytokinetics Presents Data from Heart Failure Program; Presentation Supports Advancement of CK-1827452 Towards Clinical Development

July 20, 2005: Cytokinetics to Announce Second Quarter Results on July 27, 2005

June 14, 2005: Cytokinetics Files Shelf Registration Statement

June 7, 2005: Cytokinetics to Present at the Goldman Sachs Twenty-Sixth Annual Global Healthcare Conference

May 27, 2005: Cytokinetics to Present at the Pacific Growth Equities 2005 Life Sciences Growth Conference

May 25, 2005: Cytokinetics to Present at the Friedman Billings Ramsey 9th Annual Growth Investor Conference

May 18, 2005: Cytokinetics to Present at the Needham & Company Fourth Annual Biotechnology Conference

May 14, 2005: Cytokinetics Announces Interim Phase I Results for SB-743921 at the 2005 Annual Meeting of the American Society of Clinical Oncology

May 12, 2005: Cytokinetics to Hold Annual Meeting of Stockholders

May 10, 2005: Cytokinetics to Present at the Banc of America Securities Health Care Conference 2005

April 27, 2005: Cytokinetics, Incorporated Reports First Quarter 2005 Financial Results; Company Provides Update on Development Programs

April 25, 2005: Cytokinetics to Present at the Deutsche Bank 30th Annual Health Care Conference

April 20, 2005: Cytokinetics to Announce First Quarter Results on April 27, 2005

April 5, 2005: Cytokinetics Announces Changes to Board of Directors

April 5, 2005: Cytokinetics Announces Interim Phase I Results for SB-743921 to be Presented at the 2005 Annual Meeting of the American Society of Clinical Oncology

March 31, 2005: Cytokinetics to Present at the BioCentury Future Leaders in the Biotech Industry Conference

March 3, 2005: Cytokinetics Announces Selection of Heart Failure Drug Development Candidate

February 16, 2005: Cytokinetics to Present at the BIO CEO & Investor Conference 2005

February 3, 2005: Cytokinetics, Incorporated Reports Fourth Quarter and Year End 2004 Financial Results; Company Provides Update on Development Programs

January 27, 2005: Cytokinetics to Release Fourth Quarter and Year End 2004 Financial Results on February 3, 2005

2004

December 16, 2004: Cytokinetics Announces the Initiation of an Additional Phase II Clinical Trial for Lead Cancer Drug Candidate

December 8, 2004: Cytokinetics Presents Research Data from Heart Failure Program; Additional Presentations at the American Society of Cell Biology Meeting Span Multiple Therapeutic Areas

November 30, 2004: Cytokinetics Announces Eleven Abstracts to Be Presented at the 44th Annual American Society of Cell Biology Meeting

November 23, 2004: Cytokinetics to Present at the Lazard Life Sciences Conference

November 11, 2004: Cytokinetics to Present at the Credit Suisse First Boston Annual Heathcare Conference

November 8, 2004: Cytokinetics Announces Data from Heart Failure Drug Discovery Program Presented at the 2004 Scientific Sessions of the American Heart Association

November 3, 2004: Cytokinetics Announces Research Data from Heart Failure Program at the American Heart Association Annual Meeting

November 2, 2004: Cytokinetics Announces Research Data from Heart Failure Program at the American Heart Association Annual Meeting

October 22, 2004: Cytokinetics to Present at the Rodman and Renshaw Conference

October 21, 2004: Cytokinetics, Incorporated Reports Third Quarter Financial Results; Company Reports Progress in Oncology and Cardiovascular Programs

October 14, 2004: Cytokinetics to Announce Third Quarter Results on October 21, 2004

October 7, 2004: Cytokinetics to Present at the Bio Emerging Company Investor Forum Conference

July 28, 2004: Cytokinetics, Incorporated Reports Second Quarter Financial Results; Company Completed IPO and Advanced Drug Candidates in Collaboration with GlaxoSmithKline

July 23, 2004: Cytokinetics to Present at the Banc of America Securities Specialty Pharmaceuticals Conference

July 21, 2004: Cytokinetics to Announce Second Quarter Results on July 28, 2004

June 16, 2004: Cytokinetics, Incorporated Reports 2004 First Quarter Financial Results; Company Progresses Clinical Pipeline while Advancing Research Programs

June 10, 2004: Cytokinetics to Present at the Third Annual Needham Biotechnology Conference

June 9, 2004: Cytokinetics to Announce First Quarter Results on June 16, 2004

June 8, 2004: Cytokinetics To Present At Pacific Growth Equities’ Life Sciences Growth Conference

June 7, 2004: Cytokinetics Announces Phase I Results for SB-715992 Presented at the 2004 Annual Meeting of the American Society of Clinical Oncology

June 3, 2004: Cytokinetics to Present at Goldman Sachs Twenty Fifth Annual Global Healthcare Conference

June 2, 2004: Cytokinetics Announces Phase I Results for SB-715992 to be Presented at the 2004 Annual Meeting of the American Society of Clinical Oncology

May 27, 2004: Cytokinetics to Present at Friedman, Billings, Ramsey’s 8th Annual Growth Investor Conference

May 17, 2004: Cytokinetics to Present at Bank of America Securities Health Care Conference

May 13, 2004: Cytokinetics Announces the Initiation of Phase I Clinical Trial for SB-743921 in Cancer Patients with Solid Tumors

May 4, 2004: Cytokinetics, Incorporated Announces Closing Of Its Initial Public Offering And Exercise Of Underwriters’ Option To Purchase Additional Shares

May 3, 2004: Cytokinetics Publication in Cancer Research Demonstrates Antitumor Activity of a Kinesin Spindle Protein – KSP – Inhibitor in a Preclinical Model

April 29, 2004: Cytokinetics, Incorporated Announces Its Initial Public Offering

April 4, 2004: Cytokinetics, Incorporated Announces Closing Of Its Initial Public Offering And Exercise Of Underwriters’ Option To Purchase Additional Shares

March 29, 2004: Cytokinetics, Incorporated Announces Its Initial Public Offering

January 27, 2004: Cytokinetics, Inc. Files for Initial Public Offering

January 14, 2004: Cytokinetics Announces the Initiation of a Broad Phase II Clinical Trials Program in Oncology for SB-715992; Milestone Payment Triggered under Collaboration with GlaxoSmithKline

2003

December 18, 2003: Cytokinetics Announces Technology Development Collaboration with AstraZeneca Focused on Predictive Toxicity

December 11, 2003: Cytokinetics Sponsors Third Special Interest Subgroup on Interface Between Small Molecule Chemistry and Cell Biology

April 28, 2003: Cytokinetics Completes Mezzanine Stage Financing; Two New Board Members Named

2002

December 12, 2002: Cytokinetics Sponsors Second Special Interest Subgroup on Cytoskeletal Pharmacology and Human Disease

August 12, 2002: Cytokinetics Announces the Initiation of Phase I Clinical Trial

April 8, 2002: Cytokinetics And GlaxoSmithKline Announce Seven Presentations At The 2002 Annual Meeting Of The American Association For Cancer Research

January 9, 2002: Cytokinetics Announces Cytometrix™ Technologies Development Partner Program

January 3, 2002: Exelixis And Cytokinetics Establish Chemistry Collaboration

2001

September 21, 2001: Cytokinetics Announces Milestone Payment on Selection of Oncology Development Candidate By GlaxoSmithKline

June 25, 2001: Cytokinetics and GlaxoSmithKline Form Major Strategic Alliance in Cancer Drug Discovery

2000

December 8, 2000: Cytokinetics Sponsors Special Interest Subgroup On The Cytoskeleton And Mechanisms Of Disease

November 27, 2000: Cytokinetics Completes $55.0 Million Series C Financing

1999

September 9, 1999: Cytokinetics Closes $20.0 Million Series B Financing

1998

December 16, 1998: Cytokinetics, Inc. Formed to Leverage Cytoskeleton for Drug Discovery and Bioinformatics